The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy

Wenning, Gregor K.; Stanković, Iva; Vignatelli, Luca; Fanciulli, Alessandra; Calandra‐Buonaura, Giovanna; Seppi, Klaus; Palma, Jose‐Alberto; Meissner, Wassilios G.; Krismer, Florian; Berg, Daniela; Cortelli, Pietro; Freeman, Roy; Halliday, Glenda M.; Höglinger, Günter U.; Lang, Anthony E.; Ling, Helen; Litvan, Irene; Low, Phillip A.; Miki, Yasuo; Panicker, Jalesh N.; Pellecchia, Maria Teresa; Quinn, Niall; Sakakibara, Ryuji; Stamelou, María; Tolosa, Eduardo; Tsuji, Shoji; Warner, Thomas T.; Poewe, Werner

doi:10.1002/mds.29005

Cited by 329 publications

(343 citation statements)

References 82 publications

Supporting

Mentioning

287

Contrasting

Unclassified

Order By: Relevance

“…Although severe urinary incontinence in the first 5 years of disease is a red flag of PD diagnosis, long-standing or small amount stress incontinence in women should be excluded. Unexplained urge incontinence was a supportive diagnostic criterion of MSA according to the newest MSA diagnostic (Wenning et al, 2022 ). These criteria suggest simply functional incontinence alone is not enough to distinguish Parkinson's disease from multisystem atrophy.…”

Section: Discussionmentioning

confidence: 99%

“…Urinary incontinence and retention are crucial symptoms of LUTS. PD patients were generally considered less likely to develop those two symptoms, and the presence of unexplained voiding difficulties with elevated post-void residual (PVR) volume ≥ 100 ml or unexplained urinary urge incontinence was often considered to support the diagnosis of multiple system atrophy (MSA) (Yamamoto et al, 2016 ; Wenning et al, 2022 ). However, urinary incontinence and retention are not rare, even PVR volume ≥ 100 ml can also occur in PD (Irene, 2019 ; Tateno et al, 2021 ).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Prevalence of lower urinary tract symptoms, urinary incontinence and retention in Parkinson's disease: A systematic review and meta-analysis

Cui

Yan

et al. 2022

Front. Aging Neurosci.

View full text Add to dashboard Cite

BackgroundLower urinary tract symptoms (LUTS) are common non-motor symptoms but are often overlooked in Parkinson's disease (PD). The prevalence of LUTS in PD is inconsistent among different studies.ObjectiveTo estimate the prevalence of LUTS, urinary incontinence, and urinary retention in PD patients, then, investigate potential sources of inconsistency in prevalence estimation.MethodsWe searched PubMed, EMBASE, and Web of Science databases from inception to May 2022. Studies reporting the prevalence of LUTS or LUTS subtypes in PD were included. Pooled prevalence of LUTS, LUTS subtypes, urinary incontinence, and urinary retention was calculated via random-effects models. Meta-regression and subgroup analyses were performed.ResultsOf 7,358 studies after duplicate removal, a total of 73 studies comprising 14,937 PD patients were included. The pooled prevalence of LUTS was 61% (95% CI 53–69; 27 studies; n = 5,179), while the pooled prevalence of storage symptoms and voiding symptoms was 59% (44–73; 9 studies; n = 798) and 24% (14–33; 11 studies; n = 886), respectively. The pooled prevalence of urinary incontinence, retention and post-void residual (PVR) volume ≥ 100 ml were 30% (95% CI 22–39; 21 studies; n = 6,054), 27% (17–37; 14 studies; n = 1,991), and 4% (1–7; 5 studies; n = 439), respectively. The prevalence of LUTS, urinary incontinence, or urinary retention was significantly associated with diagnostic methods.ConclusionLUTS and its subtypes present in a significant proportion of PD patients. It is necessary to use standardized and validated methods to detect and screen LUTS and its subtypes.Systematic review registration:https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022311233, Identifier: CRD42022311233.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Prevalence of lower urinary tract symptoms, urinary incontinence and retention in Parkinson's disease: A systematic review and meta-analysis

Cui

Yan

et al. 2022

Front. Aging Neurosci.

View full text Add to dashboard Cite

show abstract

“…In clinical routine, the diagnoses of neurodegenerative PS are based on distinct diagnostic criteria. These usually consist of core criteria, supportive criteria, and exclusion criteria (Postuma et al 2015 ; Höglinger et al 2017 ; Wenning et al 2022 ). However, these clinical criteria only allow the prediction of the underlying pathology with a certain probability.…”

Section: Diagnostic and Pathophysiological Aspects Of Parkinson’s Dis...mentioning

confidence: 99%

“…Furthermore, the sensitivity of the previous MSA diagnostic criteria was low at first visit (Osaki et al 2009 ). Moreover, recent diagnostic criteria for PSP and MSA allow to make diagnoses at earlier staged by the introduction of “suggestive of PSP” (Höglinger et al 2017 ) or “possible prodromal multiple system atrophy” (Wenning et al 2022 ) as diagnostic certainty levels. However, there is always a trade-off between sensitivity and specificity.…”

Section: Diagnostic and Pathophysiological Aspects Of Parkinson’s Dis...mentioning

confidence: 99%

“…In the new diagnostic criteria for multiple system atrophy, a novel “possible prodromal MSA” stage was established (Wenning et al 2022 ). This stage mainly relies on the presence of RBD and has to be prospective evaluated for sensitivity and specificity of detection of patients eventually developing possible or probable MSA.…”

Section: Diagnostic and Pathophysiological Aspects Of Parkinson’s Dis...mentioning

confidence: 99%

See 1 more Smart Citation

Disease modification in Parkinsonism: obstacles and ways forward

2022

View full text Add to dashboard Cite

To date, the diagnoses of Parkinson syndromes are based on clinical examination. Therefore, these specific diagnoses are made, when the neuropathological process is already advanced. However, disease modification or neuroprotection, is considered to be most effective before marked neurodegeneration has occurred. In recent years, early clinical or prodromal stages of Parkinson syndromes came into focus. Moreover, subtypes of distinct diseases will allow predictions of the individual course of the diseases more precisely. Thereby, patients will be enrolled into clinical trials with more specific disease entities and endpoints. Furthermore, novel fluid and imaging biomarkers that allow biochemical diagnoses are under development. These will lead to earlier diagnoses and earlier therapy in the future as consequence. Furthermore, therapeutic approaches will take the underlying neuropathological process of neurodegenerative Parkinson syndromes more specific into account. Specifically, future therapies will target the aggregation of aggregation-prone proteins such as alpha-synuclein and tau, the degradation of pathological aggregates, and the spreading of pathological protein aggregates throughout the brain. Many of these approaches are already in (pre)clinical development. In addition, anti-inflammatory approaches are in development. Furthermore, drug-repurposing is a feasible approach to shorten the developmental process of new drugs.

show abstract

Movement Disorders

Foltynie,

Bhatia,

Cordivari

et al. 2024

Neurology

View full text Add to dashboard Cite

The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy

Abstract: This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Cited by 329 publications

References 82 publications

Prevalence of lower urinary tract symptoms, urinary incontinence and retention in Parkinson's disease: A systematic review and meta-analysis

Prevalence of lower urinary tract symptoms, urinary incontinence and retention in Parkinson's disease: A systematic review and meta-analysis

Disease modification in Parkinsonism: obstacles and ways forward

Movement Disorders

Contact Info

Product

Resources

About